AR011077A1 - Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion - Google Patents

Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion

Info

Publication number
AR011077A1
AR011077A1 ARP980100207A ARP980100207A AR011077A1 AR 011077 A1 AR011077 A1 AR 011077A1 AR P980100207 A ARP980100207 A AR P980100207A AR P980100207 A ARP980100207 A AR P980100207A AR 011077 A1 AR011077 A1 AR 011077A1
Authority
AR
Argentina
Prior art keywords
methylerythromycin
solvate
mammal
suspension
bacterial infections
Prior art date
Application number
ARP980100207A
Other languages
English (en)
Spanish (es)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR011077A1 publication Critical patent/AR011077A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ARP980100207A 1997-01-17 1998-01-16 Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion AR011077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin

Publications (1)

Publication Number Publication Date
AR011077A1 true AR011077A1 (es) 2000-08-02

Family

ID=25136084

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980100207A AR011077A1 (es) 1997-01-17 1998-01-16 Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion
ARP030101427A AR039666A2 (es) 1997-01-17 2003-04-24 Procedimiento para la preparacion de la forma i de 6-o-metileritromicina a al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para prepararla forma i de 6-o-metileritromicina a y otros derivados
ARP030101428A AR039667A2 (es) 1997-01-17 2003-04-24 Procedimiento para la preparacion de la forma ii de 6-o-metileritromicina al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para preparar la forma ii de 6-o-metileritromicina a y otros derivados

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP030101427A AR039666A2 (es) 1997-01-17 2003-04-24 Procedimiento para la preparacion de la forma i de 6-o-metileritromicina a al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para prepararla forma i de 6-o-metileritromicina a y otros derivados
ARP030101428A AR039667A2 (es) 1997-01-17 2003-04-24 Procedimiento para la preparacion de la forma ii de 6-o-metileritromicina al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para preparar la forma ii de 6-o-metileritromicina a y otros derivados

Country Status (18)

Country Link
US (1) US5945405A (enExample)
EP (1) EP1077988A1 (enExample)
JP (3) JP4058114B2 (enExample)
KR (1) KR100567149B1 (enExample)
CN (1) CN1174991C (enExample)
AR (3) AR011077A1 (enExample)
AU (1) AU735598B2 (enExample)
BR (1) BR9714287A (enExample)
CA (4) CA2387356C (enExample)
CZ (1) CZ297433B6 (enExample)
DE (1) DE97951771T1 (enExample)
ES (1) ES2173058T1 (enExample)
IL (1) IL130255A0 (enExample)
NZ (1) NZ336073A (enExample)
TR (1) TR199901578T2 (enExample)
TW (1) TW574224B (enExample)
WO (1) WO1998031699A1 (enExample)
ZA (1) ZA98116B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
CN1666991A (zh) * 1999-12-16 2005-09-14 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法和新的多晶型物ⅳ
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
CN1450903A (zh) 2000-01-11 2003-10-22 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
CA2401571A1 (en) * 2000-02-29 2001-09-07 Ilya Avrutov Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
DE60122791T2 (de) * 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
AU6381201A (en) * 2000-03-28 2001-10-08 Biochemie Gmbh Granulated particles with masked taste
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ATE485837T1 (de) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
JP2004537566A (ja) * 2001-08-01 2004-12-16 ブリストル−マイヤーズ　スクイブ　カンパニー 味マスキング組成物
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
WO2009023191A2 (en) * 2007-08-09 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
CA2261732C (en) * 1996-07-29 2001-07-24 Abbott Laboratories Preparation of crystal form ii of clarithromycin
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Also Published As

Publication number Publication date
CZ297433B6 (cs) 2006-12-13
JP2004075689A (ja) 2004-03-11
AU735598B2 (en) 2001-07-12
US5945405A (en) 1999-08-31
BR9714287A (pt) 2000-04-18
AU5532698A (en) 1998-08-07
CN1244869A (zh) 2000-02-16
JP2000509725A (ja) 2000-08-02
AR039666A2 (es) 2005-03-02
DE97951771T1 (de) 2004-07-08
CA2387361A1 (en) 1998-07-23
CA2387356C (en) 2003-05-27
CA2419499A1 (en) 1998-07-23
WO1998031699A1 (en) 1998-07-23
EP1077988A1 (en) 2001-02-28
CA2277274C (en) 2003-05-27
CN1174991C (zh) 2004-11-10
KR100567149B1 (ko) 2006-04-04
NZ336073A (en) 2001-01-26
TW574224B (en) 2004-02-01
CA2277274A1 (en) 1998-07-23
KR20000070220A (ko) 2000-11-25
JP5190350B2 (ja) 2013-04-24
JP2009137975A (ja) 2009-06-25
CA2387361C (en) 2003-05-27
ES2173058T1 (es) 2002-10-16
IL130255A0 (en) 2000-06-01
AR039667A2 (es) 2005-03-02
CA2387356A1 (en) 1998-07-23
ZA98116B (en) 1998-07-08
TR199901578T2 (xx) 1999-09-21
CZ242699A3 (cs) 1999-11-17
JP4058114B2 (ja) 2008-03-05

Similar Documents

Publication Publication Date Title
AR011077A1 (es) Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion
RU95106362A (ru) Производные липопептида, способ их получения, содержащая их фармацевтическая композиция и способ ее получения
NO2005020I1 (no) Caspofungin, eventuelt i form av et farmasøytisk akseptabelt salt særlig caspofunginacetat
DE69425671D1 (de) Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
ES2196331T3 (es) Derivados macrociclicos de cadena de 13 elementos de las eritromicinas a y b.
SE7613959L (sv) Antibiotisk komposition och forfarande for framstellning derav
DE69728420D1 (de) Methoden zur behandlung von durch chlamydia pneumoniae verursachten herzkrankheiten
AP9801253A0 (en) 9-Oxime erythromycin derivatives.
BR9603429A (pt) Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado
PT1042340E (pt) Oxima de 6-o-alquil-eritromicina b
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
YU1396A (sh) 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima
EP0992509A3 (en) Novel macrolide derivatives
AR005642A1 (es) Compuestos antibioticos de cefalosporina, uso de los mismos para preparar composiciones farmaceuticas, dichas composiciones farmaceuticas que los comprenden,compuestos intermediarios de aplicacion en la preparacion de los primeros y metodo para elaborar dichos compuestos intermediarios
BR9708930A (pt) Composto derivado de 3-descladinose-2,3-anidro-eritromicina ou um seu sal ou éster farmaceuticamente aceitável processo para a preparação do composto composição farmacêutica e processo de tratamento de infecções bacterianas
DE2967701D1 (de) A-21978 genannte antibiotische mischung, verfahren zu ihrer herstellung, ihre pharmazeutischen zusammensetzungen und produzierender mikroorganismus.
MD1788F2 (en) Erythromycin A 9-O-oximes derivatives, pharmaceutical composition on base thereof and method of treatment of infectious diseases
DE69012650D1 (de) Piperidinderivat, Verfahren zur Herstellung davon und dieses enthaltende pharmazeutische Zusammensetzung.
ES2157899T3 (es) Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
ATE66610T1 (de) Primycin enthaltendes kolloidales grundgel, verfahren zu dessen herstellung, dieses grundgel enthaltende pharmazeutische und pharmako- kosmetische kompositionen.
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
RU94007342A (ru) Новые производные эритромицина, метод их получения и фармацевтическая композиция на их основе
HUT57774A (en) Process for producing triacetate derivative of antibiotic bu-3420t, as well as pharmaceutical compositions comprising bu-3420t triacetate

Legal Events

Date Code Title Description
FC Refusal